Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Protectimmun Teams Up With Johnson & Johnson Innovation and Imperial College under a Research Fund..


Protectimmun Teams Up With Johnson & Johnson Innovation and Imperial College under a Research Funding Agreement

Gelsenkirchen, Germany, September 28, 2015 - Protectimmun GmbH, a biopharmaceutical R&D company, announced today that it has entered into a research funding agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Imperial College, London. The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research conducted at Imperial College by Prof Clare Lloyd with one of Protectimmun’s lead candidates in a proof-of-concept disease model of allergic asthma developed by Prof Lloyd.

“We are very pleased about the opportunity to strengthen and expand our preclinical data package for this program through this collaboration”, said Marion Kauth, Ph.D., co-founder and Chief Executive Officer of Protectimmun. “This agreement strongly supports our ambition to pave the way for a disruptive first-in-class approach to combat allergic asthma and hay fever.”

Protectimmun focusses on new approaches in the prevention and therapy of allergic and chronic inflammatory diseases. Its innovative concept for product development is based on the identification of natural substances and bacteria with immunomodulatory properties from particular farm environments which are selectively transferred into pharmaceutical applications. Promising candidates that were successfully tested in proof-of-concept animal models of asthma are currently in mid- to late-stage preclinical development.

”It is impressive to see Johnson & Johnson Innovation’s strong commitment to creating new types of early-stage R&D collaborations to foster innovative healthcare solutions”, added Marcus Peters, PhD, board member of Protectimmun.


Contact

Protectimmun GmbH
Marion Kauth, PhD, CEO
+49 209 389 66 556
info@protectimmun.de
http://www.protectimmun.de


Publisher Contact Information:

Protectimmun
+49 209 389 66 556
info@protectimmun.de

Company profile of Protectimmun
Past press releases of Protectimmun.

Data


24,503
Tech investments
From our Online Data Service
15,853
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jul 6€47.0MBiotechnology
Jul 6€15.0MWireless applications
Jul 6€13.0MInternet services
Jul 6€7.0MBiopharmaceuticals
Jul 5€11.0MWireless applications
Jul 4€30.0MConsumer electronics
Jul 4€14.0MSensors

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

May 4
Vivet Therapeutics
vivet therapeutics raises €37.5 million in series a





About usContact usLegal Information
Copyright © 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.